Glaukos Updates Full-Year 2026 Net Sales Guidance
Glaukos Corporation issued updated full-year 2026 net sales guidance, projecting a range of $775 million to $785 million, surpassing analyst expectations.
Stocks · News reference
Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics To Develop And Commercialize RO-104, A Novel Tri-Specific Biologic
Development targeted for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The agreement also grants Glaukos
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Glaukos Corporation Reports Q3 2026 Financial Results
Glaukos Corporation announced its third-quarter 2026 financial results, reporting revenue of $211.0 million, which exceeded the FactSet consensus estimate of $168.0 million.
8-K filing — GLAUKOS Corp (GKOS)
Filed: 2026-10-28 AccNo: 0001193125-26-436147 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala
Forge's Fierce Life Sciences announced finalists for the 2026 Fierce Life Science and Healthcare Innovation Awards, recognizing breakthrough innovations across AI, biotechnology, digital health, and medical devices. The inaugural Fierce Vanguard Gala on November 19, 2026, in New York City will consolidate three recognition programs (Fierce 50, Fierce 15, and Innovation Awards) and announce winners live.